SLC2A5 and type 2 diabetes mellitus: The inhibition of intestinal LCFA, glucose and fructose transporters is a promising target regarding the prevention and treatment of not only metabolic disorders such as T2DM, but also other diseases which are correlated with high blood concentration of these food components.